Cargando…

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared propertie...

Descripción completa

Detalles Bibliográficos
Autores principales: Verginelli, Federica, Pisacane, Alberto, Gambardella, Gennaro, D’Ambrosio, Antonio, Candiello, Ermes, Ferrio, Marco, Panero, Mara, Casorzo, Laura, Benvenuti, Silvia, Cascardi, Eliano, Senetta, Rebecca, Geuna, Elena, Ballabio, Andrea, Montemurro, Filippo, Sapino, Anna, Comoglio, Paolo M., Boccaccio, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093243/
https://www.ncbi.nlm.nih.gov/pubmed/33941777
http://dx.doi.org/10.1038/s41467-021-22643-w
_version_ 1783687775678103552
author Verginelli, Federica
Pisacane, Alberto
Gambardella, Gennaro
D’Ambrosio, Antonio
Candiello, Ermes
Ferrio, Marco
Panero, Mara
Casorzo, Laura
Benvenuti, Silvia
Cascardi, Eliano
Senetta, Rebecca
Geuna, Elena
Ballabio, Andrea
Montemurro, Filippo
Sapino, Anna
Comoglio, Paolo M.
Boccaccio, Carla
author_facet Verginelli, Federica
Pisacane, Alberto
Gambardella, Gennaro
D’Ambrosio, Antonio
Candiello, Ermes
Ferrio, Marco
Panero, Mara
Casorzo, Laura
Benvenuti, Silvia
Cascardi, Eliano
Senetta, Rebecca
Geuna, Elena
Ballabio, Andrea
Montemurro, Filippo
Sapino, Anna
Comoglio, Paolo M.
Boccaccio, Carla
author_sort Verginelli, Federica
collection PubMed
description Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and propagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly disseminating, and forming widespread established metastases. Regardless of different genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a transcriptomic signature predicting that more than 70% of CUP patients could be eligible to MEK inhibition. These data shed light on CUP biology and unveil an opportunity for therapeutic intervention.
format Online
Article
Text
id pubmed-8093243
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80932432021-05-11 Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition Verginelli, Federica Pisacane, Alberto Gambardella, Gennaro D’Ambrosio, Antonio Candiello, Ermes Ferrio, Marco Panero, Mara Casorzo, Laura Benvenuti, Silvia Cascardi, Eliano Senetta, Rebecca Geuna, Elena Ballabio, Andrea Montemurro, Filippo Sapino, Anna Comoglio, Paolo M. Boccaccio, Carla Nat Commun Article Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and propagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly disseminating, and forming widespread established metastases. Regardless of different genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a transcriptomic signature predicting that more than 70% of CUP patients could be eligible to MEK inhibition. These data shed light on CUP biology and unveil an opportunity for therapeutic intervention. Nature Publishing Group UK 2021-05-03 /pmc/articles/PMC8093243/ /pubmed/33941777 http://dx.doi.org/10.1038/s41467-021-22643-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Verginelli, Federica
Pisacane, Alberto
Gambardella, Gennaro
D’Ambrosio, Antonio
Candiello, Ermes
Ferrio, Marco
Panero, Mara
Casorzo, Laura
Benvenuti, Silvia
Cascardi, Eliano
Senetta, Rebecca
Geuna, Elena
Ballabio, Andrea
Montemurro, Filippo
Sapino, Anna
Comoglio, Paolo M.
Boccaccio, Carla
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title_full Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title_fullStr Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title_full_unstemmed Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title_short Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
title_sort cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to mek inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093243/
https://www.ncbi.nlm.nih.gov/pubmed/33941777
http://dx.doi.org/10.1038/s41467-021-22643-w
work_keys_str_mv AT verginellifederica cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT pisacanealberto cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT gambardellagennaro cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT dambrosioantonio cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT candielloermes cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT ferriomarco cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT paneromara cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT casorzolaura cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT benvenutisilvia cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT cascardieliano cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT senettarebecca cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT geunaelena cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT ballabioandrea cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT montemurrofilippo cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT sapinoanna cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT comogliopaolom cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition
AT boccacciocarla cancerofunknownprimarystemlikecellsmodelmultiorganmetastasisandunveilliabilitytomekinhibition